peer-reviewed research papers published since 2017
h-index score of our Founder and CEO, Eric Schadt, Ph.D.
PhDs and MDs currently employed at Sema4
large next generation sequencing (NGS) panels run
We’re proud to welcome Gustavo Stolovitzky, Ph.D., as Chief Science Officer of Sema4. Dr. Stolovitzky is a globally-acclaimed expert in computational biology, disease modeling, and nano-biotechnology with over 25 years of experience in high throughput data analysis for biology and the application of technology to solve biomedical problems. He will lead the advancement of Sema4’s strategic research direction to enable healthcare systems to deliver cutting-edge translational medicine to providers and patients.
As a research partner, Sema4 can support a range of studies, from optimizing biomarker discovery to leveraging our biorepository services and accelerating clinical trial enrollment. We can bring a range of capabilities to partnerships, including:
We currently partner with numerous pharmaceutical companies, major health systems, research consortia, clinicians, and advocacy groups.